CR10091A - Compuestos orgánicos - Google Patents

Compuestos orgánicos

Info

Publication number
CR10091A
CR10091A CR10091A CR10091A CR10091A CR 10091 A CR10091 A CR 10091A CR 10091 A CR10091 A CR 10091A CR 10091 A CR10091 A CR 10091A CR 10091 A CR10091 A CR 10091A
Authority
CR
Costa Rica
Prior art keywords
organic compounds
treatment
disease
depends
renin
Prior art date
Application number
CR10091A
Other languages
English (en)
Inventor
Takeru Ehara
Philipp Grosche
Osamu Irie
Yuki Iwaki
Takanori Kanazawa
Shimple Kawakami
Kazuhide Konishi
Muneto Mogi
Masaki Suzuki
Fumiaki Yokokawa
Original Assignee
Canada Export S A
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37875514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0604223A external-priority patent/GB0604223D0/en
Priority claimed from GB0611390A external-priority patent/GB0611390D0/en
Application filed by Canada Export S A, Novartis Ag filed Critical Canada Export S A
Publication of CR10091A publication Critical patent/CR10091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de piperidina 3,5- sustituida, a estos compuestos para utilizarse en el diagnóstico y en el tratamiento terapéutico de un animal de sangre caliente, en especial para el tratamiento de una enfermedad (=trastorno) que dependa de la actividad de la renina; al uso de un compuesto de esta clase para la preparación de una formulación farmacéutica para el tratamiento de una enfermedad que dependa de la actividad de la renina.
CR10091A 2005-12-30 2008-06-19 Compuestos orgánicos CR10091A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028771 2005-12-30
GB0604223A GB0604223D0 (en) 2006-03-02 2006-03-02 Organic compounds
GB0611390A GB0611390D0 (en) 2006-06-08 2006-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
CR10091A true CR10091A (es) 2008-10-27

Family

ID=37875514

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10091A CR10091A (es) 2005-12-30 2008-06-19 Compuestos orgánicos

Country Status (20)

Country Link
US (1) US8129411B2 (es)
EP (2) EP1968940B1 (es)
JP (1) JP5306821B2 (es)
KR (1) KR20080086921A (es)
AR (1) AR058885A1 (es)
AU (1) AU2006332124B2 (es)
BR (1) BRPI0620736A2 (es)
CA (1) CA2633624C (es)
CR (1) CR10091A (es)
EC (1) ECSP088587A (es)
ES (2) ES2476422T3 (es)
IL (1) IL192024A0 (es)
MA (1) MA30073B1 (es)
NO (1) NO20083315L (es)
NZ (1) NZ569135A (es)
PE (2) PE20110117A1 (es)
PL (1) PL2420491T3 (es)
PT (1) PT2420491E (es)
TW (1) TW200738698A (es)
WO (1) WO2007077005A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
JP5484069B2 (ja) 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体
KR101403311B1 (ko) 2008-05-05 2014-06-05 액테리온 파마슈티칼 리미티드 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
NZ600238A (en) 2008-06-19 2014-04-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20120115907A1 (en) * 2009-04-24 2012-05-10 Cadila Healthcare Limited Novel compounds as inhibitors of renin
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
KR20140092696A (ko) * 2013-01-16 2014-07-24 주식회사유한양행 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
EP3130581A4 (en) 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102579582B1 (ko) * 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
CN119059970B (zh) * 2024-08-30 2026-03-24 上海信诺维生物医药有限公司 一种btk抑制剂药物中间体的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5463074A (en) 1991-12-18 1995-10-31 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
JP2000500502A (ja) * 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP1009405A4 (en) 1997-08-28 2001-05-09 Merck & Co Inc PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
WO2000026211A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3386700A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
WO2001074741A2 (en) * 2000-04-04 2001-10-11 Brandeis University Catalytic asymmetric desymmetrization of meso compounds
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
CA2425288A1 (en) 2000-10-11 2002-05-02 Sander G. Mills Pyrrolidine modulators of ccr5 chemokine receptor activity
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
CA2483241C (en) 2002-04-29 2011-05-31 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivatives
JP4271148B2 (ja) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CN1780836A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
JP2007523845A (ja) 2003-04-29 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
KR20060006069A (ko) 2003-04-30 2006-01-18 액테리온 파마슈티칼 리미티드 아자비사이클로노넨 유도체
JP2006524657A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規トロパン誘導体
KR20060008937A (ko) 2003-04-30 2006-01-27 액테리온 파마슈티칼 리미티드 레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
EP1622564A2 (en) 2003-05-02 2006-02-08 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
CA2540543A1 (en) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives
CN1906163A (zh) 2003-11-26 2007-01-31 诺瓦提斯公司 作为肾素抑制剂的4－苯基哌啶衍生物
JP4884230B2 (ja) 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
BRPI0506491A (pt) 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
EP1711456A2 (en) 2004-01-23 2006-10-18 Speedel Experimenta AG Amino alcohol derivatives and their use as renin inhibitors
ATE472524T1 (de) 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
EP1724259A1 (en) 2004-03-19 2006-11-22 Speedel Experimenta AG 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
US20080176947A1 (en) 2005-03-11 2008-07-24 Peter Herold Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
BRPI0609534A2 (pt) 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
CA2622375A1 (en) 2005-09-17 2007-03-22 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
BRPI0617166A2 (pt) 2005-09-17 2011-07-12 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão
PE20071079A1 (es) 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
JP2009525304A (ja) 2006-01-30 2009-07-09 シュペーデル・エクスペリメンタ・アーゲー α，β−不飽和化合物からのアルコールの立体選択的製造方法
TW200815425A (en) 2006-06-08 2008-04-01 Speedel Experimenta Ag 2,5-disubstituted piperidines
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors

Also Published As

Publication number Publication date
MA30073B1 (fr) 2008-12-01
AU2006332124A1 (en) 2007-07-12
ECSP088587A (es) 2008-07-30
PT2420491E (pt) 2013-10-14
WO2007077005A1 (en) 2007-07-12
EP2420491B1 (en) 2013-07-03
IL192024A0 (en) 2008-12-29
EP1968940A1 (en) 2008-09-17
TW200738698A (en) 2007-10-16
PL2420491T3 (pl) 2013-12-31
EP1968940B1 (en) 2014-04-02
NO20083315L (no) 2008-09-19
ES2476422T3 (es) 2014-07-14
BRPI0620736A2 (pt) 2011-12-20
AU2006332124B2 (en) 2011-03-03
PE20110117A1 (es) 2011-03-07
CA2633624A1 (en) 2007-07-12
ES2430139T3 (es) 2013-11-19
JP5306821B2 (ja) 2013-10-02
EP2420491A1 (en) 2012-02-22
PE20071177A1 (es) 2008-01-18
JP2009522226A (ja) 2009-06-11
NZ569135A (en) 2011-08-26
US8129411B2 (en) 2012-03-06
KR20080086921A (ko) 2008-09-26
CA2633624C (en) 2013-11-19
AR058885A1 (es) 2008-02-27
US20090192148A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CR10091A (es) Compuestos orgánicos
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
GT200500359A (es) Compuestos organicos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
ECSP055525A (es) Inhibidores de cinasas de tirosina
GT200500307A (es) Compuestos quimicos
ECSP12007431A (es) Compuestos orgánicos
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
PA8680701A1 (es) Derivados de oxindol
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
GT200600114A (es) Derivados de ciclopropanocarboxamida
UY30736A1 (es) Compuestos quimicos 537
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
ATE534736T1 (de) Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)